Reuters logo
1 年前
BRIEF-Kite Pharma presents responses in Phase 1 of ZUMA-1 in chemorefractory non-Hodgkin lymphoma patients
2016年6月6日 / 中午12点02分 / 1 年前

BRIEF-Kite Pharma presents responses in Phase 1 of ZUMA-1 in chemorefractory non-Hodgkin lymphoma patients

1 分钟阅读

June 6 (Reuters) - Kite Pharma Inc :

* Kite Pharma presents ongoing complete responses at 9 months in phase 1 of ZUMA-1 in patients with chemorefractory non-Hodgkin lymphoma

* Says "results showed that treatment with KTE-C19 achieved rapid and durable responses in patients with chemorefractory disease" Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below